- Trials with a EudraCT protocol (97)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
97 result(s) found for: Bile duct.
Displaying page 1 of 5.
EudraCT Number: 2010-023345-30 | Sponsor Protocol Number: RAD-IPMT | Start Date*: 2010-11-18 | |||||||||||
Sponsor Name:U.L.S.S. 9 DI TREVISO | |||||||||||||
Full Title: Prospective spontaneous cross-over study on pancreatic T1/T2 enhancement in patients with IPMT: comparison Omniscan-Dotarem | |||||||||||||
Medical condition: Pancreatic intraductal papillary mucinous tumor | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002605-25 | Sponsor Protocol Number: AIO-HEP-0120 | Start Date*: 2021-03-24 | |||||||||||||||||||||||||||||||
Sponsor Name:AIO-Studien-gGmbH | |||||||||||||||||||||||||||||||||
Full Title: Neoadjuvant Bintrafusp alfa in patients with resectable biliary tract cancer (NEOBIL) | |||||||||||||||||||||||||||||||||
Medical condition: Treatment-naive subjects with a diagnosis of resectable biliary tract cancer, confirmed by histopathology | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-004762-83 | Sponsor Protocol Number: BILISCOPIN | Start Date*: 2008-10-15 | ||||||||||||||||||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | ||||||||||||||||||||||||||||
Full Title: Evaluation of the diagnostic efficacy of the CT cholangiography performed by administering an intra-venous contrast medium with biliary excretion (Biliscopin) in patients with malignancies of the b... | ||||||||||||||||||||||||||||
Medical condition: Patients with obstructive jaundice due to a biliary malignancy (Klatskin tumor, tumor of the middle or distal bile ducts or Galbladder tumors) Patients with post-cholecistectomy iatrogenic lesions ... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004866-17 | Sponsor Protocol Number: 01/2005 | Start Date*: 2007-04-03 |
Sponsor Name:Dept Medicine I, Paracelsus Med. Univ. Landeskrankenanstalten Salzburg / SALK | ||
Full Title: An Open-label, single arm Phase II Trial of Photodynamic Therapy using Foscan for non-curatively-resectable bile duct carcinoma | ||
Medical condition: Nonresectable hilar or extrahepatic bile duct carcinoma in clinical stage MO ( without liver or peritoneal metastases according to clinical or surgical staging) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-013408-30 | Sponsor Protocol Number: 2009-013408-30 | Start Date*: 2010-08-23 | |||||||||||||||||||||
Sponsor Name:University College London | |||||||||||||||||||||||
Full Title: Randomised phase II trial of cediranib (AZD2171) vs. placebo in addition to cisplatin / gemcitabine chemotherapy for patients with advanced biliary tract cancers | |||||||||||||||||||||||
Medical condition: biliary tract carcinomas (including gallbladder cancer and cholangiocarcinomas) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-017428-17 | Sponsor Protocol Number: 20091105 | Start Date*: 2010-05-31 | ||||||||||||||||||||||||||
Sponsor Name:AZIENDA OSPEDALIERA ORDINE MAURIZIANO | ||||||||||||||||||||||||||||
Full Title: A Phase II Randomized Clinical Trial of Panitumumab plus Gemcitabine and Oxaliplatin (GEMOX) versus GEMOX alone as First Line Treatment in Advanced Biliary Tract Adenocarcinoma | ||||||||||||||||||||||||||||
Medical condition: advanced intrahepatic colangiocarcinoma and extrahepatic biliary adenocarcinoma including gallbladder | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004693-42 | Sponsor Protocol Number: 747-206 | Start Date*: 2015-06-29 | ||||||||||||||||
Sponsor Name:Intercept Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Multicenter, Open Label, Single- and Multiple-Dose, Dose Finding Study to Assess the Effects of Obeticholic Acid in Pediatric Subjects with Biliary Atresia | ||||||||||||||||||
Medical condition: Biliary atresia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended) FI (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) ES (Ongoing) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-002629-95 | Sponsor Protocol Number: 170188 | Start Date*: 2022-08-02 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Department of vascular surgery, Lillebaelt Hospital | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Cefuroxime and Piperacillin Concentrations in the Biliary System | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Infection in the biliary system such as cholecystitis and cholangitis both as acute infections and post-operative infections. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003392-30 | Sponsor Protocol Number: 15-0106 | Start Date*: 2016-04-18 | |||||||||||||||||||||||||||||||
Sponsor Name:NGM Biopharmaceuticals, Inc. | |||||||||||||||||||||||||||||||||
Full Title: A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF NGM282 ADMINISTERED FOR 12 WEEKS IN PATIENTS WIT... | |||||||||||||||||||||||||||||||||
Medical condition: PRIMARY SCLEROSING CHOLANGITIS (PSC) | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) NL (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-003217-11 | Sponsor Protocol Number: NL82304.058.22 | Start Date*: 2023-02-24 | |||||||||||||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||||||||||||
Full Title: Standard versus Pre-emptive Antibiotic Treatment to Reduce the Rate of Infectious Outcomes after Whipple procedure (SPARROW): a multicenter, randomized controlled trial | |||||||||||||||||||||||
Medical condition: Pancreatic head malignancy | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014886-21 | Sponsor Protocol Number: BA_BICG_UMCG_1 | Start Date*: 2010-01-26 |
Sponsor Name:University Medical Centre Groningen | ||
Full Title: Intraoperative bile duct visualisation in children with biliary atresia using a fluorescence camera system: a pilot study | ||
Medical condition: Biliary atresia | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004176-21 | Sponsor Protocol Number: CMC-P005 | Start Date*: 2007-10-01 |
Sponsor Name:CMC Contrast AB c/o Öresund Health Care Management | ||
Full Title: Evaluation of the diagnostic efficacy of CMC-001 (MnCl2 tetrahydrate) in MR cholangiography in patients with suspected liver lesions. A randomised, parallel group, open-label Phase II trial. | ||
Medical condition: Liver lesions. CMC-001 is an orally administered contrast medium containing manganese (Mn) as the active imaging substance. Manganese is absorbed by the healthy parts of the liver and will thus cre... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003166-42 | Sponsor Protocol Number: CSTI571BDE55 | Start Date*: 2005-12-27 | |||||||||||
Sponsor Name:University of Leipzig | |||||||||||||
Full Title: Palliative Chemotherapy (2nd line) with Imatinib (GlivecTM) in Patients with Bile Duct Cancer. | |||||||||||||
Medical condition: Patients with histologically proven adenocarcinoma of the gallbladder/bile duct (not papillary cancer) in an advanced stage, who have not responded to a first line chemotherapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004217-14 | Sponsor Protocol Number: P21.128 | Start Date*: 2022-11-09 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: FLUOPANC-trial - Intraoperative near-infrared fluorescence imaging in pancreatic- and extrahepatic bile duct tumors using cRGD-ZW800-1 and dedicated imaging systems: A phase II feasibility, dose-ra... | ||
Medical condition: Pancreatic cancer (pancreatic carcinoma) Extrahepatic bile duct cancer (cholangiocarcinoma) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-020480-21 | Sponsor Protocol Number: pro-duct001 | Start Date*: 2010-11-18 |
Sponsor Name:Universitätsmedizin Charite | ||
Full Title: Feasibility and efficacy of adjuvant gemcitabine chemotherapy after liver transplantation for proximal bile duct cancer | ||
Medical condition: proximal bile duct cancer | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-002495-18 | Sponsor Protocol Number: SG2006/1 | Start Date*: 2007-04-08 | |||||||||||
Sponsor Name:Wrightington, Wigan and Leigh NHS Trust | |||||||||||||
Full Title: The use of ketamine in combination with midazolam for the induction of conscious sedation during endoscopic retrograde cholangiopancreatography (ERCP). | |||||||||||||
Medical condition: The study will not investigate any specific disease, but rather the sedation techniques used for endoscopic retrograde cholangiopancreatography, a form of endoscopy which can be used to diagnose an... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004224-22 | Sponsor Protocol Number: TEMOPEDI | Start Date*: 2015-12-08 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Université catholique de Louvain | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Temocillin pharmacokinetics in paediatrics | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Male or female patient requiring temocillin a. for the treatment of urinary tract infections, or b. for the treatment of suspicion of cholangitis associated with cirrhosis, or c. as antibiotic pro... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004415-39 | Sponsor Protocol Number: TO-TAS0728-101 | Start Date*: 2019-02-05 | |||||||||||||||||||||||||||||||
Sponsor Name:Taiho Oncology, Inc. | |||||||||||||||||||||||||||||||||
Full Title: A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF TAS0728, AN ORAL COVALENT BINDING INHIBITOR OF HER2, IN SUBJECTS WITH ADVANCED SOLID TUMORS W... | |||||||||||||||||||||||||||||||||
Medical condition: Urothelial cancer with HER2 or HER3 mutation Biliary tract cancer with HER2 or HER3 mutation Breast cancer with HER2 or HER3 mutation Breast cancer with HER2 amplification/overexpression as per AS... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) ES (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-003807-37 | Sponsor Protocol Number: A4250-011 | Start Date*: 2020-07-29 | |||||||||||
Sponsor Name:Albireo AB | |||||||||||||
Full Title: A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy (BOLD) | |||||||||||||
Medical condition: Biliary Atresia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) DE (Ongoing) BE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001200-20 | Sponsor Protocol Number: CSET 1287 | Start Date*: 2007-06-01 |
Sponsor Name:Institut Gustave Roussy | ||
Full Title: A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine – Oxaliplatin Chemotherapy Alone or in Combination with Cetuximab in Patients with Advanced Biliary Cancer | ||
Medical condition: adenocarcinoma of the biliary tract ( gallbladder, intra and/ or extrahepatic bile ducts, ampulla of Vater) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) DE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
